HLVX — HilleVax Income Statement
0.000.00%
Last trade - 00:00- $92.76m
- -$78.67m
- 19
- 44
- 18
- 16
Annual income statement for HilleVax, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.29 | 53.4 | 65.1 | 133 | 157 |
| Operating Profit | -1.29 | -53.4 | -65.1 | -133 | -157 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.1 | -102 | -160 | -124 | -147 |
| Net Income After Taxes | -2.1 | -102 | -160 | -124 | -147 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.1 | -102 | -160 | -124 | -147 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.1 | -102 | -160 | -124 | -147 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.066 | -2.05 | -5.79 | -3.04 | -1.98 |
| Dividends per Share |